Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
5
×
boston blog main
boston top stories
deals
life sciences
national blog main
biotech
national top stories
alexion pharmaceuticals
boehringer ingelheim
clinical trials
eli lilly
fda
san francisco blog main
san francisco top stories
alnylam pharmaceutials
amyotrophic lateral sclerosis (als)
arrowhead pharmaceuticals
atrial fibrillation
autoimmune disorders
biontech
biopharma
boston scientific
clinical trial
complement system
cryterion medical
curevac
dicerna pharmaceuticals
duchenne
europe blog main
europe top stories
food and drug administration
generalized myasthenia gravis
hepatitis b
immune-mediated necrotizing myopathy
indiana blog main
indiana top stories
infectious diseases
investing
john shiver
What
deal
5
×
medicines
rna
companies
pharma
second
time
abandoning
acquire
adding
ago
alternative
approval
atrial
autoimmune
baggage
bets
betting
billion
bio
biopharma
boston
business
cancer
candidate
comes
continues
cryterion
cut
cuts
date
development
device
dicerna
disease
drug
duchenne
effective
enticed
evidence
Language
unset
Current search:
boston
×
deal
×
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
Boston Scientific Continues M&A Streak with $202M Deal for Cryterion
@xconomy.com
5 years ago
With $45M Translate Bio Deal, Sanofi Bets Again on mRNA Vaccines